• HoldiPharma and US-based Dawah Pharma to launch a pharma export joint venture
• Dawah will hold 60%, HoldiPharma 40%, with initial focus on US-approved supplements
• The JV targets expansion into regulated markets like North America and Europe

Egypt’s state-owned pharmaceutical group HoldiPharma has signed a partnership with US-based Dawah Pharma to create a joint venture focused on manufacturing and exporting pharmaceuticals and dietary supplements. The deal, announced by the Egyptian government on May 29, aims to boost self-sufficiency and increase exports, particularly to North America and Europe.

The agreement was signed under the supervision of Prime Minister Mostafa Madbouly. Dawah Pharma will hold a 60% stake in the new entity, while HoldiPharma will retain 40%. The joint venture will begin by exporting six food supplements that have already been approved for the US market.

Future phases include manufacturing and exporting a wider range of pharmaceutical products such as ampoules, sterile injections, ophthalmic drugs, and over-the-counter medications. The venture will also introduce advanced manufacturing technologies for syrups, tablets, pre-filled syringes, and transdermal patches.

The products will comply with international standards set by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), helping to raise the global profile of Egyptian-made pharmaceuticals.

As the Arab world’s most populous nation, Egypt is actively building partnerships with international firms to strengthen its pharmaceutical industry, reduce medicine shortages, and expand exports. According to Fitch Solutions, Egypt’s 180 pharmaceutical factories increased their exports by 65.6% in the previous year, reaching $447.1 million.